Omadacycline Noninferior to Moxifloxacin for Pneumonia

WEDNESDAY, Feb. 6, 2019 -- Omadacycline is noninferior to moxifloxacin for community-acquired bacterial pneumonia and noninferior to linezolid for acute bacterial skin infections, according to two studies published in the Feb. 7 issue of the New...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

This study estimated the prevalence of bacterial pneumonia in HIV patients, antimicrobial susceptibility patterns of pathogens implicated in pneumonia, and associated risk factors in Mekelle zone, Tigray, Northern Ethiopia, during August-December 2016. Methods: Sputum specimens were collected from 252 HIV seropositive individuals with suspected pneumonia. Data on sociodemographics and risk factors were also collected using a structured questionnaire. Blood, Chocolate, and Mac Conkey agar plates (Oxoid, Hampshire, UK) were used to grow the isolates. The isolated colonies were identified based on Gram stain, colony morp...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Background: The need for antimicrobial therapies effective against multidrug resistant organisms for children remains unmet. Tigecycline shows antibacterial activity across a broad spectrum of bacteria and is approved for treating complicated skin and skin-structure infections, complicated intra-abdominal infections and, in the United States, community-acquired bacterial pneumonia for adult patients. No blinded, randomized phase 3 tigecycline clinical trials on neonates or children have been completed or planned. This review aimed to provide a comprehensive synthesis of all the existing data sources, both on-label and of...
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Antimicrobial Reports Source Type: research
TUESDAY, June 11, 2019 -- Zerbaxa (ceftolozane and tazobactam) has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older, the...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Abstract Solithromycin (CEM-101) is a novel fluoroketolide antimicrobial agent with activity against typical and atypical pathogens associated with community-acquired bacterial pneumonia. Using a neutropenic murine-lung infection model, the objectives of this study were to identify the pharmacokinetic/pharmacodynamic (PK/PD) index most closely associated with efficacy and the magnitude of such indices necessary for solithromycin efficacy against Streptococcus pneumoniae Plasma and epithelial lining fluid (ELF) samples for pharmacokinetics (PK) were collected serially over 24 hours from healthy mice administered si...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research
The objective of these analyses was to develop a population pharmacokinetic model to describe the arbekacin concentration-time profile in plasma and epithelial lining fluid (ELF) following ME1100 administration. Data were obtained from a post-marketing study for an IV formulation of arbekacin, a Phase 1 study of ME1100 in healthy volunteers, and a Phase 1b study of ME1100 in mechanically ventilated subjects with bacterial pneumonia. Data from the post-marketing study were utilized to develop a population pharmacokinetic model following IV administration and this model was subsequently utilized as the foundation for develop...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research
Authors: Kumar S, Mishra M, Goyal K, Bhatt R, Joshi P, Bansal S Abstract Acute fibrinous organizing pneumonia (AFOP) is a rare, non-infective lung pathology histologically characterized by patchy distribution of intra-alveolar fibrin "balls" and organizing pneumonia. It needs to be differentiated from other forms of acute pneumonia like community acquired pneumonia (CAP) because the treatment modalities are contrastingly different. Interesting case of a 45-year-old male initially suspected as a case of acute bacterial pneumonia but finally diagnosed as case of AFOP, is being reported. Initial empirical an...
Source: Monaldi Archives for Chest Disease - Category: Respiratory Medicine Tags: Monaldi Arch Chest Dis Source Type: research
The previously FDA-approved drug, Zerbaxa, is now indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
TUESDAY, June 4, 2019 -- Zerbaxa (ceftolozane and tazobactam) has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older, the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
FDA today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
Zerbaxa (ceftolozane and tazobactam) for hospital- and ventilator-associated bacterial pneumonia was initially approved for complicated intra-abdominal and urinary tract infections.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Pulmonary Medicine News Alert Source Type: news
More News: Avelox | Bacterial Pneumonia | Linezolid | Moxifloxacin | Pharmaceuticals | Pneumonia | Skin | Study | Zyvox